Interpore Cross
This article was originally published in The Gray Sheet
Executive Summary
Launch of the firm's Pro Osteon 500R resorbable bone void filler is anticipated by year end following FDA market go-ahead, announced Sept. 29. Intended for bony voids or gaps in the skeletal system, including the extremities, spine and pelvis, the product's calcium carbonate pores are layered with calcium phosphate, allowing for "biocompatibility along with predictable resorption characteristics," Interpore says. The Irvine, California-based firm plans to combine the product with its autologous growth factors technology, and looks to market a next-generation product in mid-1999